carmustine has been researched along with Cancer of Skin in 102 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 9.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "A total of 21 adult patients (11 male, 10 female)with early-stage (IA-IIA) refractory CTCL, mycosis fungoides type, treated with topical carmustine following intravenous O6-benzylguanine." | 9.16 | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. ( Apisarnthanarax, N; Carlson, S; Chan, DV; Cooper, KD; Fu, P; Gerson, SL; Gilliam, AC; Liu, L; Remick, SC; Stevens, SR; Szabo, SK; Wood, GS, 2012) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 9.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "One hundred seventy-six eligible patients with advanced melanoma were randomized to receive CT (cisplatin and dacarbazine with or without carmustine every 21 days) or bioCT comprising the same CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week, both for six cycles." | 9.10 | Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. ( Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P, 2002) |
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 9.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)." | 9.09 | A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. ( Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N, 2000) |
| "A prospective randomized phase III clinical trial was conducted to assess whether the addition of tamoxifen (TAM) to the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progression-free survival and overall survival of patients with advanced malignant melanoma." | 9.09 | Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. ( Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM, 1999) |
| "In this multicenter phase III trial, 240 patients with measurable stage IV melanoma were randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m(2) and cisplatin 25 mg/m(2) days 1 to 3, carmustine 150 mg/m(2) day 1 every other cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1, 000 mg/m(2)." | 9.09 | Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. ( Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM, 1999) |
| "Since cytotoxic chemotherapy (BCNU, DTIC and cisplatin, tamoxifen) and interferon-alpha (IFN-alpha) have each produced responses in advanced malignant melanoma, a phase II trial was conducted to evaluate the response and toxicity of simultaneous administration of both therapies." | 9.08 | Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. ( Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N, 1995) |
| "We designed and conducted a randomized, double-blind, placebo-controlled trial to compare the response rates and survival of patients with metastatic melanoma who received carmustine (BCNU), dacarbazine (DTIC), and cisplatin with tamoxifen, or the same chemotherapy with placebo." | 9.08 | Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. ( Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B, 1996) |
| "The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized." | 8.82 | Topical carmustine (BCNU) in the treatment of mycosis fungoides. ( Zackheim, HS, 2003) |
| "This article summarizes experience with topical carmustine (BCNU) solution in 172 patients with patch/plaque stage mycosis fungoides." | 7.69 | Topical carmustine (BCNU) for patch/plaque mycosis fungoides. ( Zackheim, HS, 1994) |
| "A prospective, nonrandomized trial was performed of the four-drug chemotherapy protocol consisting of dacarbazine, carmustine, cisplatin, and tamoxifen citrate given to high-risk patients for recurrence of melanoma after local regional treatment." | 7.68 | Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. ( Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE, 1992) |
| "One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)." | 7.68 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 7.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "A 10-year experience in eighty-six patients confirms the effectiveness of topical carmustine (BCNU) in mycosis fungoides (MF)." | 7.66 | Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. ( Crain, WR; Epstein, EH; Grekin, DA; McNutt, NS; Zackheim, HS, 1983) |
| "The total percutaneous absorption of 1,3-bis(2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in 5 patients with mycosis fungoides, based on the 5 day urinary excretion of 14C-labelled BCNU, ranged from 5 to 28%." | 7.65 | Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides. ( Feldmann, RJ; Lindsay, C; Maibach, HI; Zackheim, HS, 1977) |
| "Melanoma is rare in Singapore with an age-standardised rate (ASR) of 0." | 6.68 | Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. ( Ang, PT; Tan, EH, 1996) |
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 5.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "A total of 21 adult patients (11 male, 10 female)with early-stage (IA-IIA) refractory CTCL, mycosis fungoides type, treated with topical carmustine following intravenous O6-benzylguanine." | 5.16 | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. ( Apisarnthanarax, N; Carlson, S; Chan, DV; Cooper, KD; Fu, P; Gerson, SL; Gilliam, AC; Liu, L; Remick, SC; Stevens, SR; Szabo, SK; Wood, GS, 2012) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 5.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "One hundred seventy-six eligible patients with advanced melanoma were randomized to receive CT (cisplatin and dacarbazine with or without carmustine every 21 days) or bioCT comprising the same CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week, both for six cycles." | 5.10 | Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. ( Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P, 2002) |
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 5.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "In this multicenter phase III trial, 240 patients with measurable stage IV melanoma were randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m(2) and cisplatin 25 mg/m(2) days 1 to 3, carmustine 150 mg/m(2) day 1 every other cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1, 000 mg/m(2)." | 5.09 | Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. ( Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM, 1999) |
| "The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)." | 5.09 | A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. ( Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N, 2000) |
| "The combination of carmustine, cisplatin, dacarbazine, interferon, and low-dose tamoxifen is widely used in treating metastatic melanoma and was originally reported to achieve a 20% complete response rate." | 5.09 | Sustained complete remission after chemobiohormonal therapy for metastatic melanoma. ( Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M, 1999) |
| "A prospective randomized phase III clinical trial was conducted to assess whether the addition of tamoxifen (TAM) to the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progression-free survival and overall survival of patients with advanced malignant melanoma." | 5.09 | Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. ( Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM, 1999) |
| "Since cytotoxic chemotherapy (BCNU, DTIC and cisplatin, tamoxifen) and interferon-alpha (IFN-alpha) have each produced responses in advanced malignant melanoma, a phase II trial was conducted to evaluate the response and toxicity of simultaneous administration of both therapies." | 5.08 | Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. ( Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N, 1995) |
| "We designed and conducted a randomized, double-blind, placebo-controlled trial to compare the response rates and survival of patients with metastatic melanoma who received carmustine (BCNU), dacarbazine (DTIC), and cisplatin with tamoxifen, or the same chemotherapy with placebo." | 5.08 | Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. ( Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B, 1996) |
| "The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized." | 4.82 | Topical carmustine (BCNU) in the treatment of mycosis fungoides. ( Zackheim, HS, 2003) |
| "The two major topical treatment modalities for cutaneous T-cell lymphoma (CTCL) are mechlorethamine (nitrogen mustard) and topical carmustine (BCNU)." | 4.79 | Topical treatment of early cutaneous T-cell lymphoma. ( Meller, JA; Ramsay, DL; Zackheim, HS, 1995) |
| "This article summarizes experience with topical carmustine (BCNU) solution in 172 patients with patch/plaque stage mycosis fungoides." | 3.69 | Topical carmustine (BCNU) for patch/plaque mycosis fungoides. ( Zackheim, HS, 1994) |
| "One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)." | 3.68 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990) |
| "A prospective, nonrandomized trial was performed of the four-drug chemotherapy protocol consisting of dacarbazine, carmustine, cisplatin, and tamoxifen citrate given to high-risk patients for recurrence of melanoma after local regional treatment." | 3.68 | Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. ( Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE, 1992) |
| " The water-soluble ACNU (nimustine) is an alternative to other nitrosoureas in the treatment of gliomas." | 3.68 | Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma. ( Dahl, O; Schem, BC, 1991) |
| "Eight patients with advanced malignant melanoma were treated with high-dose melphalan (80-90 mg/m2) and BCNU (600-800 mg/m2)." | 3.67 | High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma. ( Havemann, K; Koeppler, H; Pflueger, KH; Seitz, R, 1989) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 3.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily." | 3.67 | Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987) |
| "A 10-year experience in eighty-six patients confirms the effectiveness of topical carmustine (BCNU) in mycosis fungoides (MF)." | 3.66 | Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. ( Crain, WR; Epstein, EH; Grekin, DA; McNutt, NS; Zackheim, HS, 1983) |
| "The total percutaneous absorption of 1,3-bis(2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in 5 patients with mycosis fungoides, based on the 5 day urinary excretion of 14C-labelled BCNU, ranged from 5 to 28%." | 3.65 | Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides. ( Feldmann, RJ; Lindsay, C; Maibach, HI; Zackheim, HS, 1977) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "Twenty-six patients with mycosis fungoides were treated topically with three nitrosourea compounds: carmustine (BCNU), lomustine (CCNU), and 1-methyl-1-nitrosourea." | 3.65 | Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies. ( Epstein, EH; Zackheim, HS, 1975) |
| "Melanoma is rare in Singapore with an age-standardised rate (ASR) of 0." | 2.68 | Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. ( Ang, PT; Tan, EH, 1996) |
| "Cerebral metastases were the sole or major cause of death in 8/9 patients who relapsed following control with DTIC for nine months or longer, and one patient developed a carcinoma of the breast following therapy with DTIC and BCNU." | 2.64 | Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). ( Berris, R; Hill, GJ; Parkin, P; Philpott, GW; Ruess, R, 1974) |
| " The BCNU@HCLI system was chosen to develop gel and cream semisolid dosage forms." | 1.46 | Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice. ( Ghiciuc, CM; Grigorovici, A; Ignat, M; Lupusoru, CE; Ochiuz, L; Solcan, C; Stoleriu, I; Strat, AL; Vasile, A, 2017) |
| "The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment." | 1.29 | Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. ( Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M, 1994) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| "HN2 was a potent carcinogen, producing squamous cell carcinomas in 9 of 33 mice in 1 series." | 1.26 | Tumorigenic effect of topical mechlorethamine, BCNU and CCNU in mice. ( Smuckler, EA; Zackheim, HS, 1980) |
| "Mycosis fungoides is a T-cell lymphoma which is often localized to the skin in the early stages." | 1.26 | Topical chemotherapy of mycosis fungoides. ( Epstein, EH; Grekin, DA; Zackheim, HS, 1979) |
| "All patients had extensive metastases in soft tissues, intestines and, some of them, in bone." | 1.26 | [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)]. ( Kleeberg, UR; Schreml, W, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (45.10) | 18.7374 |
| 1990's | 26 (25.49) | 18.2507 |
| 2000's | 22 (21.57) | 29.6817 |
| 2010's | 7 (6.86) | 24.3611 |
| 2020's | 1 (0.98) | 2.80 |
| Authors | Studies |
|---|---|
| Charifa, A | 1 |
| Paulson, N | 1 |
| Levy, L | 1 |
| Perincheri, S | 1 |
| Lee, A | 1 |
| McNiff, JM | 1 |
| Ko, CJ | 1 |
| Ghiciuc, CM | 1 |
| Strat, AL | 1 |
| Ochiuz, L | 1 |
| Lupusoru, CE | 1 |
| Ignat, M | 1 |
| Vasile, A | 1 |
| Grigorovici, A | 1 |
| Stoleriu, I | 1 |
| Solcan, C | 1 |
| de Quintana-Sancho, A | 1 |
| Acebo-Mariñas, E | 1 |
| Gardeazabal-García, J | 1 |
| Aperribay-Esparza, A | 1 |
| MacArthur, KM | 1 |
| Jariwala, N | 1 |
| Kim, EJ | 1 |
| Rook, AH | 1 |
| Tacastacas, JD | 1 |
| Chan, DV | 2 |
| Carlson, S | 2 |
| Gerson, SL | 2 |
| Dowlati, A | 1 |
| Fu, P | 2 |
| Lu, K | 1 |
| Groft, S | 1 |
| Rosenjack, J | 1 |
| Honda, K | 1 |
| McCormick, TS | 1 |
| Cooper, KD | 2 |
| Lupov, IP | 1 |
| Voiles, L | 1 |
| Han, L | 1 |
| Schwartz, A | 1 |
| De La Rosa, M | 1 |
| Oza, K | 1 |
| Pelloso, D | 1 |
| Sahu, RP | 1 |
| Travers, JB | 1 |
| Robertson, MJ | 1 |
| Chang, HC | 1 |
| Fenot, M | 1 |
| Maillard, H | 1 |
| Sierra-Fortuny, S | 1 |
| De Ybarlucea, LR | 1 |
| Célérier, P | 1 |
| Apisarnthanarax, N | 1 |
| Wood, GS | 1 |
| Stevens, SR | 1 |
| Liu, L | 1 |
| Szabo, SK | 1 |
| Gilliam, AC | 1 |
| Remick, SC | 1 |
| Wolchok, JD | 1 |
| Williams, L | 1 |
| Pinto, JT | 1 |
| Fleisher, M | 1 |
| Krown, SE | 1 |
| Hwu, WJ | 1 |
| Livingston, PO | 1 |
| Chang, C | 1 |
| Chapman, PB | 2 |
| Bodell, WJ | 1 |
| Giannini, DD | 1 |
| Singh, S | 1 |
| Pietronigro, D | 1 |
| Levin, VA | 1 |
| Ridolfi, R | 3 |
| Tanganelli, L | 1 |
| Scelzi, E | 1 |
| Manente, P | 1 |
| Palmeri, S | 1 |
| Ravaioli, A | 1 |
| Fiammenghi, L | 1 |
| Romanini, A | 3 |
| Chiarion-Sileni, V | 2 |
| Del Bianco, P | 1 |
| De Salvo, GL | 1 |
| Lo Re, G | 2 |
| Labianca, R | 2 |
| Nortilli, R | 2 |
| Corgna, E | 1 |
| Dalla Palma, M | 1 |
| Lo Presti, G | 1 |
| Akimov, MA | 1 |
| Gel'fond, ML | 1 |
| Gershanovich, ML | 1 |
| Barchuk, AS | 1 |
| Lens, MB | 1 |
| Eisen, TG | 1 |
| Zackheim, HS | 17 |
| Feun, L | 1 |
| Marini, A | 1 |
| Moffat, F | 2 |
| Savaraj, N | 2 |
| Hurley, J | 2 |
| Mazumder, A | 1 |
| Dummer, R | 1 |
| Foss, F | 1 |
| Dreno, B | 1 |
| Bagot, M | 1 |
| Hsiao, PF | 1 |
| Hsiao, CH | 1 |
| Tsai, TF | 1 |
| Jee, SH | 1 |
| Li, RH | 1 |
| Tam, WH | 1 |
| Ng, PC | 1 |
| Mok, TS | 1 |
| Tam, B | 1 |
| Lau, TK | 1 |
| Pitman, J | 1 |
| Muekusch, G | 1 |
| Estève, E | 1 |
| Grange, F | 1 |
| Costanzi, JJ | 2 |
| Fletcher, WS | 1 |
| Balcerzak, SP | 1 |
| Taylor, S | 1 |
| Eyre, HJ | 1 |
| O'Bryan, RM | 2 |
| Al-Sarraf, M | 1 |
| Frank, J | 1 |
| Hill, GJ | 2 |
| Krementz, ET | 1 |
| Hill, HZ | 1 |
| Epstein, EH | 7 |
| McNutt, NS | 2 |
| Grekin, DA | 4 |
| Crain, WR | 3 |
| Klemm-Mayer, H | 1 |
| Rasokat, H | 1 |
| Wagner, G | 1 |
| Wheeler, KT | 1 |
| Wallen, CA | 1 |
| Wolf, KL | 1 |
| Siemann, DW | 1 |
| Robertson, DM | 1 |
| Wilkinson, CP | 1 |
| Murray, JL | 1 |
| Gordy, DD | 1 |
| Smuckler, EA | 1 |
| Snyder, RD | 1 |
| Hortobagyi, GN | 1 |
| Bodey, GP | 2 |
| Gutterman, JU | 1 |
| Hersh, EM | 2 |
| Feun, LG | 1 |
| Robinson, D | 1 |
| Liebmann, A | 1 |
| Raub, WA | 1 |
| Richman, SP | 1 |
| Schadendorf, D | 1 |
| Worm, M | 1 |
| Algermissen, B | 1 |
| Kohlmus, CM | 1 |
| Czarnetzki, BM | 1 |
| Herrmann, JJ | 1 |
| Roenigk, HH | 1 |
| Hurria, A | 1 |
| Kuzel, TM | 1 |
| Samuelson, E | 1 |
| Rademaker, AW | 1 |
| Rosen, ST | 1 |
| Atzpodien, J | 3 |
| Lopez Hänninen, E | 1 |
| Kirchner, H | 1 |
| Franzke, A | 1 |
| Körfer, A | 1 |
| Volkenandt, M | 1 |
| Duensing, S | 1 |
| Schomburg, A | 1 |
| Chaitchik, S | 1 |
| Poliwoda, H | 2 |
| Moreau, P | 1 |
| LeTortorec, S | 1 |
| Mahé, MA | 1 |
| Mahé, B | 1 |
| Moreau, A | 1 |
| Bourdin, S | 1 |
| Bulabois, CE | 1 |
| Bureau, B | 1 |
| Harousseau, JL | 1 |
| Milpied, N | 1 |
| Ramsay, DL | 1 |
| Meller, JA | 1 |
| Rusthoven, JJ | 1 |
| Quirt, IC | 1 |
| Iscoe, NA | 1 |
| McCulloch, PB | 1 |
| James, KW | 1 |
| Lohmann, RC | 1 |
| Jensen, J | 1 |
| Burdette-Radoux, S | 1 |
| Bodurtha, AJ | 1 |
| Silver, HK | 1 |
| Verma, S | 1 |
| Armitage, GR | 1 |
| Zee, B | 1 |
| Bennett, K | 1 |
| Kirchner, HH | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Thompson, JA | 1 |
| Gold, PJ | 1 |
| Fefer, A | 1 |
| Richard-Lallemand, MA | 1 |
| Carsuzaa, F | 1 |
| Verret, JL | 1 |
| Rousselet, MC | 1 |
| Peria, P | 1 |
| Stein, ME | 1 |
| Bernstein, Z | 1 |
| Drumea, K | 1 |
| Zalik, M | 1 |
| Shklar, Z | 1 |
| Steiner, M | 1 |
| Haim, N | 1 |
| Creagan, ET | 1 |
| Suman, VJ | 1 |
| Dalton, RJ | 1 |
| Pitot, HC | 1 |
| Long, HJ | 1 |
| Veeder, MH | 1 |
| Vukov, AM | 1 |
| Rowland, KM | 1 |
| Krook, JE | 1 |
| Michalak, JC | 1 |
| Einhorn, LH | 2 |
| Meyers, ML | 1 |
| Saxman, S | 1 |
| Destro, AN | 1 |
| Panageas, KS | 1 |
| Begg, CB | 1 |
| Agarwala, SS | 1 |
| Schuchter, LM | 1 |
| Ernstoff, MS | 1 |
| Houghton, AN | 1 |
| Kirkwood, JM | 1 |
| Heald, PW | 1 |
| Glusac, EJ | 1 |
| Thomson, KF | 1 |
| Sheehan-Dare, RA | 1 |
| Wilkinson, SM | 1 |
| Middleton, MR | 1 |
| Lorigan, P | 1 |
| Owen, J | 1 |
| Ashcroft, L | 1 |
| Lee, SM | 1 |
| Harper, P | 1 |
| Thatcher, N | 1 |
| Keilholz, U | 1 |
| Suciu, S | 1 |
| Eggermont, AM | 1 |
| Dillman, RO | 1 |
| Soori, G | 1 |
| Wiemann, MC | 1 |
| Schulof, R | 1 |
| Dobbs, TW | 1 |
| Ruben, RH | 1 |
| DePriest, CB | 1 |
| Church, C | 1 |
| Jelić, S | 1 |
| Babovic, N | 1 |
| Kovcin, V | 1 |
| Milicevic, N | 1 |
| Milanovic, N | 1 |
| Popov, I | 1 |
| Radosavljevic, D | 1 |
| Neuber, K | 1 |
| Kamanabrou, D | 1 |
| Fluck, M | 1 |
| Bröcker, EB | 1 |
| Neumann, C | 1 |
| Rünger, TM | 1 |
| Schuler, G | 1 |
| von den Driesch, P | 1 |
| Müller, I | 1 |
| Paul, E | 1 |
| Patzelt, T | 1 |
| Reitz, M | 1 |
| Guida, M | 1 |
| Freschi, A | 1 |
| Brugnara, S | 1 |
| Vitali, P | 1 |
| Nanni, O | 1 |
| Volk, AL | 1 |
| Vannucci, SA | 1 |
| Cook, W | 1 |
| Thompson, KA | 1 |
| Listinsky, CM | 1 |
| Twentyman, PR | 1 |
| Epstein, JH | 1 |
| Carbone, PP | 1 |
| Costello, W | 1 |
| Hunter, JA | 1 |
| Aranha, GV | 1 |
| Grage, TB | 1 |
| Feldmann, RJ | 1 |
| Lindsay, C | 1 |
| Maibach, HI | 1 |
| Carmo-Pereira, J | 1 |
| Oliveira Costa, F | 1 |
| Pimentel, P | 1 |
| Moon, JH | 1 |
| Gailani, S | 1 |
| Cooper, MR | 1 |
| Hayes, DM | 1 |
| Rege, VB | 1 |
| Blom, J | 1 |
| Falkson, G | 2 |
| Maurice, P | 1 |
| Brunner, K | 1 |
| Glidewell, O | 1 |
| Holland, JF | 1 |
| Vaitkevicius, VK | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 2 |
| Coltman, CA | 1 |
| Delaney, FC | 2 |
| Van Dyk, JJ | 1 |
| Luce, JK | 3 |
| Kleeberg, UR | 1 |
| Schreml, W | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Saba, HI | 1 |
| Cruse, CW | 1 |
| Wells, KE | 1 |
| Klein, CJ | 1 |
| Reintgen, DS | 1 |
| Schem, BC | 1 |
| Dahl, O | 1 |
| Richards, JM | 1 |
| Bigler, RD | 1 |
| Crilley, P | 1 |
| Micaily, B | 2 |
| Brady, LW | 1 |
| Topolsky, D | 1 |
| Bulova, S | 1 |
| Vonderheid, EC | 2 |
| Brodsky, I | 1 |
| Bradford, R | 1 |
| Darling, JL | 1 |
| Thomas, DG | 1 |
| Koeppler, H | 1 |
| Pflueger, KH | 1 |
| Seitz, R | 1 |
| Havemann, K | 1 |
| McClay, EF | 2 |
| Mastrangelo, MJ | 2 |
| Sprandio, JD | 1 |
| Bellet, RE | 2 |
| Berd, D | 2 |
| Karakousis, CP | 1 |
| Emrich, LJ | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| McPherson, TA | 1 |
| Marino, C | 1 |
| Smith, C | 1 |
| O'Quinn, JL | 1 |
| Sulis, E | 1 |
| Floris, C | 1 |
| Chessa, A | 1 |
| Desogus, A | 1 |
| Muggiano, A | 1 |
| Tedde, A | 1 |
| Turno, R | 1 |
| Kardashian, JL | 1 |
| Egbert, BM | 1 |
| Clamon, G | 1 |
| Sinkey, C | 1 |
| Jochimsen, P | 1 |
| Wagenknecht, L | 1 |
| Cohen, SM | 1 |
| Greenspan, EM | 1 |
| Weiner, MJ | 1 |
| Kabakow, B | 1 |
| Primack, A | 1 |
| Dhru, D | 1 |
| Kiryabwire, JW | 1 |
| Vogel, CL | 1 |
| Minton, JP | 1 |
| Ruess, R | 1 |
| Berris, R | 1 |
| Philpott, GW | 1 |
| Parkin, P | 1 |
| Peck, GL | 1 |
| Veronesi, U | 1 |
| Bajetta, E | 1 |
| Gottlieb, JA | 2 |
| Rivkin, SE | 1 |
| Spigel, SC | 1 |
| Singhakowinta, A | 1 |
| Burgess, MA | 1 |
| Vallejos, C | 1 |
| Gutterman, J | 1 |
| Mavligit, G | 1 |
| Frei, E | 1 |
| Freireich, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma[NCT00961220] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2010-02-01 | Completed | ||
| Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma[NCT00003613] | Phase 1 | 20 participants (Anticipated) | Interventional | 1999-04-30 | Terminated | ||
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma[NCT00226473] | Phase 4 | 200 participants | Interventional | 2001-09-30 | Recruiting | ||
| Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma[NCT00683670] | Phase 1 | 17 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases[NCT01703507] | Phase 1 | 17 participants (Actual) | Interventional | 2012-11-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Based on changes in modified SWAT assessment, patient responses will be classified as complete clinical response (CCR), partial response (PR), stable disease (SD), or progressive disease (PD). SWAT provides an accurate and reproducible assessment of cutaneous disease involvement based on body surface area of involvement and lesional thickness.~CCR: No evidence of disease, 100% improvement for a duration of at least 4 weeks. PR: Greater than or equal to 50% decrease in SWAT score compared to baseline and improvement is maintained for at least 4 weeks. SD: Less than 50% decrease in SWAT score compared to baseline. PD: Increase of greater or equal to 25% of the SWAT score compared to baseline while the patient is actively taking the study drug" (NCT00961220)
Timeframe: Up to 2 weeks after completion of study treatment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Clinical Response-confirmed | Complete Clinical Response-unconfirmed | Partial Response | Progressive Disease | |
| Treatment (O6-benzylguanine, Carmustine) | 6 | 2 | 8 | 1 |
(MTD) when combined with WBRT or SRS, defined as the last dose studied or the previous dose, based on clinical judgment of the degree of toxicity seen at the last dose (NCT01703507)
Timeframe: 30 days following the completion of radiation therapy
| Intervention | mg/kg (Number) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 3 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 10 |
(NCT01703507)
Timeframe: 4 weeks following the last dose of ipilimumab
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 1 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 4 |
(NCT01703507)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 8 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 10.5 |
PFS rate based on Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC) criteria based on the brain MRI and systematic assessment by the treating physician (NCT01703507)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 3 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 3 |
(NCT01703507)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 8.2 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 1.9 |
Extracranial disease is assessed through repeated computed tomography of the chest, abdomen, and pelvis. The purpose of this scan is to determine if there is any evidence of disease outside of the brain. (NCT01703507)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 0 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 5 |
10 reviews available for carmustine and Cancer of Skin
| Article | Year |
|---|---|
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as | 2003 |
Topical carmustine (BCNU) in the treatment of mycosis fungoides.
Topics: Administration, Topical; Carmustine; Clinical Trials as Topic; Disease-Free Survival; Dose-Response | 2003 |
Treatment of cutaneous T-cell lymphoma.
Topics: Carmustine; Combined Modality Therapy; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Mechlo | 1994 |
Topical treatment of early cutaneous T-cell lymphoma.
Topics: Administration, Topical; Antineoplastic Agents, Alkylating; Carmustine; History, 20th Century; Human | 1995 |
[Mycosis fungoides].
Topics: Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Humans; Mechlorethamine; Mycosis Fungo | 1997 |
Cutaneous T cell lymphoma: update of treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Beta Particles; | 1999 |
Cutaneous malignant melanoma.
Topics: Adult; Aged; Biopsy; Carmustine; Cyclophosphamide; Dactinomycin; Female; Humans; Hydroxyurea; Male; | 1976 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
Treatment of cutaneous T-cell lymphoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Carmustine; Combined Modality Therapy; Humans; Immu | 1985 |
Chemotherapy of malignant melanoma.
Topics: Alkylating Agents; Amides; Animals; Antigen-Antibody Reactions; Antimetabolites; Antineoplastic Agen | 1972 |
30 trials available for carmustine and Cancer of Skin
| Article | Year |
|---|---|
Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemoth | 2017 |
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2012 |
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Carmusti | 2003 |
Chemotherapy and bio-chemotherapy in patients with advanced melanoma: combination therapy with a nitrosourea.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality | 2003 |
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 2003 |
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cis | 2003 |
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 2005 |
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; D | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1995 |
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 1995 |
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Dis | 1996 |
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Com | 1996 |
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 1996 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 1997 |
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; | 1999 |
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 2000 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 2000 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response | 2002 |
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 2002 |
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combi | 1976 |
Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma.
Topics: Adult; Aged; Amides; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; Humans; I | 1975 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
Adjuvant chemotherapy in high-risk malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Combined Modal | 1987 |
Triple combination chemotherapy of disseminated melanoma.
Topics: Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Combinati | 1972 |
Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Female; Follow-Up Studies; Foot; Humans; Leukocyt | 1973 |
Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).
Topics: Adult; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cyclohe | 1974 |
63 other studies available for carmustine and Cancer of Skin
| Article | Year |
|---|---|
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosph | 2020 |
Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclooxygenase 2; Drug Carriers; Mice; Proto-Oncogene Pr | 2017 |
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmusti | 2015 |
Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antine | 2017 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2011 |
[Syringotropic cutaneous T-cell lymphoma mimicking dermatomycosis].
Topics: Carmustine; Clobetasol; Dermatomycoses; Diagnostic Errors; Female; Foot Diseases; Humans; Middle Age | 2012 |
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Chromatography, High Pressure Liquid; DNA Ad | 2003 |
Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Topics: Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Dermatitis, Exfoliative; Erythem | 2006 |
Minimal residual disease in hypopigmented mycosis fungoides.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Carmustine; Humans; Male; Mycosis Fungoides; Neoplasm | 2006 |
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; H | 2007 |
Mycosis fungoides.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Carmustine; Causality; Humans; Mechlore | 2007 |
[Chlormethine (Caryolysine), carmustine (Bicnu)].
Topics: Antineoplastic Agents, Alkylating; Carmustine; Humans; Mechlorethamine; Skin Neoplasms | 2007 |
Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience.
Topics: Administration, Topical; Adult; Aged; Carmustine; Drug Administration Schedule; Female; Humans; Male | 1983 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female | 1984 |
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
Prolonged topical maintenance therapy for mycosis fungoides.
Topics: Animals; Carmustine; Humans; Mechlorethamine; Mice; Mycosis Fungoides; Skin Neoplasms | 1983 |
Mycosis fungoides presenting as areas of hypopigmentation: a report of three cases.
Topics: Adult; Aged; Carmustine; Female; Humans; Male; Mycosis Fungoides; Pigmentation Disorders; Skin Neopl | 1982 |
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neo | 1981 |
Tumorigenic effect of topical mechlorethamine, BCNU and CCNU in mice.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Carmustine; Lomustine; Mechlorethamine; Mice; Neopla | 1980 |
Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin.
Topics: Adult; Aged; Bacterial Vaccines; Carmustine; Drug Administration Schedule; Female; Heparin; Humans; | 1981 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Rel | 1994 |
Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up.
Topics: Biopsy; Carmustine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mechlorethamine; Middle | 1995 |
Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1994 |
Topical carmustine (BCNU) for patch/plaque mycosis fungoides.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Carmustine; Female; Humans; Mal | 1994 |
Time to achieve clearing with topical carmustine.
Topics: Administration, Cutaneous; Carmustine; Humans; Lymphoma, T-Cell, Cutaneous; Remission Induction; Ski | 1993 |
[Unilesional plaque-type mycosis fungoides: 3 cases].
Topics: Aged; Antineoplastic Agents, Alkylating; Carmustine; Diagnosis, Differential; Female; Follow-Up Stud | 1997 |
Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Female; Humans; | 2000 |
Allergic contact dermatitis from topical carmustine.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents, Alkylating; Carmustine; Dermatitis, Allergic | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemo | 2000 |
Composite mycosis fungoides and B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Combined Modality Therapy; | 2002 |
Treatment of mycosis fungoides with topical BCNU.
Topics: Administration, Topical; Bone Marrow; Carmustine; Drug Eruptions; Humans; Mycosis Fungoides; Remissi | 1979 |
Topical chemotherapy of mycosis fungoides.
Topics: Administration, Topical; Carmustine; Humans; Mechlorethamine; Mycosis Fungoides; Skin Neoplasms | 1979 |
Sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of the EMT6 tumor in vivo as determined by both tumor volume response and in vitro plating assay.
Topics: Animals; Carmustine; Cell Count; Cell Cycle; Cell Survival; Clone Cells; Lung Neoplasms; Male; Mamma | 1978 |
Stimulation of ultraviolet-induced carcinogenesis by 1,3-Bis(2-chloroethyl)-1-nitrosourea.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Carmustine; Female; Mice; Mice, Nude; My | 1979 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides.
Topics: Aged; Carmustine; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Absorption; Skin Neopla | 1977 |
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; | 1976 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies.
Topics: Administration, Topical; Adult; Aged; Bone Marrow; Carmustine; Cross Reactions; Drug Hypersensitivit | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lu | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Mel | 1976 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cis | 1992 |
Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Screening Assays, Antitumor; D | 1991 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cispla | 1991 |
Autologous bone marrow transplantation for advanced stage mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisp | 1991 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carmustine; Drug Administration Schedule; | 1990 |
High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1989 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematolo | 1989 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1987 |
Mycosis fungoides treated with high-dose carmustine.
Topics: Aged; Carmustine; Female; Humans; Medication Errors; Mycosis Fungoides; Skin Neoplasms | 1987 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Lymphomatoid papulosis associated with plaque-stage and granulomatous mycosis fungoides.
Topics: Administration, Topical; Carmustine; Granuloma; Humans; Male; Middle Aged; Mycosis Fungoides; Skin D | 1985 |
Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Evaluation; Female; Hu | 1985 |
Topical carmustine therapy for lymphomatoid papulosis.
Topics: Administration, Topical; Carmustine; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Dise | 1985 |
[Chemotherapy of malignant melanoma].
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Bleomycin; Carmustine; Cyclohexanes; Drug Therapy, | 1973 |
Mumps virus and BCG vaccine in metastatic melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Carmustine; Female; Humans; Imm | 1973 |
Hypertrophic scar after cryotherapy and topical tretinoin.
Topics: Administration, Topical; Carcinoma, Basal Cell; Carmustine; Cicatrix; Connective Tissue; Cryosurgery | 1973 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Agents; Carmustine; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Ski | 1973 |
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans | 1974 |
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Dexameth | 1974 |